Site is Being Upgraded

A vaccine for lowering cholesterol, and triglycerides levels: Repurposing tuberculosis BCG vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): BCG vaccine promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 30/July/2018, 12.18 am

Bacillus Calmette Guerin (BCG) vaccine-based therapy for Diabetic retinopathy: BCG vaccine inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/June/2018, 11.15 am
June 29, 2018
Carbon monoxide-based therapy for enhanced learning, memory, cognition and longevity: COR-M2(CO Releasing molecule-2)  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down regulation of its target genes, 1/July/2018, 10.27 pm
July 1, 2018
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


From Research findings to Therapeutic opportunity:

This study suggests, first the first time, Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD) . BCG vaccine  has been found to be useful in treatment for tuberculosis, for more than 100 years, more recently in the treatment of autoimmune diabetes. However, the mechanism of action remains largely unknown.

BCG vaccine, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, BCG vaccine, either alone or in combination with other drugs,may be used to treat NAFLD.

 

Figure 1. Mechanistic insights into how  tuberculosis BCG vaccine decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Repurposing tuberculosis (BCG) vaccine into a cholesterol-lowering vaccine. BCG vaccine lowers cholesterol and triglyceride levels and attenuates NAFLD through down regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does BCG vaccine decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A vaccine for lowering cholesterol, and triglycerides levels: Repurposing tuberculosis BCG vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): BCG vaccine promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 30/July/2018, 12.18 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.